Global Antimalarial Drugs Market Share Is Expected to Grow At A CAGR Value Of Around 4.2% By 2028

18-Jul-2022 | Facts and Factors

According to Facts and Factors, the global antimalarial drugs market size was valued at USD 982.50 million in 2021 and is predicted to increase at a CAGR of 4.2% to USD 1207.51 million by 2028. The study examines the market in terms of revenue in each of the major regions, which are classified into countries.

The global antimalarial pharmaceuticals market is expected to rise because of rising malaria prevalence, rising healthcare spending globally, and the presence of a high number of pipeline items. Poor demand, on the other hand, slows growth in developing countries. However, in the not-too-distant future, rising economies are projected to offer profitable prospects. Government attempts to raise awareness among the population of various emerging and underdeveloped economies are projected to propel the worldwide antimalarial medications market forward in the approaching years. Furthermore, the worldwide antimalarial medications market is likely to be driven in the near future by an increase in spending allocated to research & development efforts to produce new and advanced antimalarial drugs. In developing countries, a lack of healthcare information is a major impediment to market expansion. During the projection period, however, the growth potential of emerging economies is expected to provide profitable opportunities for market expansion.

Browse the full “Antimalarial Drugs Market Size, Share, Growth Analysis Report By Drug Class (Quinine, Chloroquine, Proguanil, Mefloquine, Pyrimethamine, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce & Other Distribution Channel), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/antimalarial-drugs-market

On the other side, in developing and undeveloped nations, a lack of awareness and access to healthcare and medical services may stymie the market's growth in the coming years. Other significant market restrictions are the possibility of antimalarial drug adverse effects and the penetration of inferior and counterfeit medicine therapies. Due to numerous profitable investments and growth prospects in emerging economies, the worldwide antimalarial pharmaceuticals market is set to expand geographically in the next years. In recent years, a massive surge in global instances of the COVID-19 virus has fuelled growth in the global antimalarial medicine market. Certain antimalarial medication products, such as hydroxychloroquine, are used to prevent the new coronavirus from infecting people by modifying the cell surface acidity. The rising potential of antimalarial medications like chloroquine in the treatment of COVID-19 is also a favorable element driving the global antimalarial drugs market forward in the approaching years.

Segmental Overview

The market for antimalarial medications was dominated by Chloroquine. Furthermore, due to the fact that malaria parasites have effectively evolved resistance to most of the medications now available on the market, the segment is predicted to increase at the quickest rate during the projection period.

In the coming years, the hospital pharmacy segment is expected to increase significantly over the forecast period. The hospital pharmacy provides an opportunity for care teams to interact in order to enhance patient outcomes. It also prevents medication errors from occurring when patients switch from one retail pharmacy to another after being discharged. As a result, over the foreseeable period, these advantages will fuel segmental expansion.

Regional Overview

Due to the region’s rapid rise in malaria prevalence, LAMEA is expected to account for the majority of the antimalarial drug market share in 2021. Furthermore, the presence of the difficult-to-control malaria vector, Anopheles gambiae, in the region is a major factor contributing to the increase in malaria cases. Furthermore, Plasmodium falciparum, the most lethal type of malaria parasite, is responsible for the vast majority of malaria infections in this region. As a result, there is a need in this region for early diagnosis of malarial infection, which drives the market growth. The ever-changing life sciences industry is driving the market's expansion.

Report Scope

Some of the major companies operating in the global antimalarial drugs market are Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), Zydus Cadila and among others.

The global antimalarial drugs market is segmented as follows:

By Drug Class

• Quinine
• Chloroquine
• Proguanil
• Mefloquine
• Pyrimethamine
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce & Other Distribution Channel

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com